Imhoff (GTHP) converts notes, exercises warrants and lifts GUIDED THERAPEUTICS common stock holdings

Rhea-AI Filing Summary

GUIDED THERAPEUTICS INC director and 10% owner John E. Imhoff reported several stock-accretive transactions. He converted portions of a September 25, 2025 convertible promissory note into 195,460, 312,720 and 156,086 shares of common stock at a conversion price of $0.07 per share, turning principal and accrued interest into equity.

Imhoff also converted 100 shares of Series E preferred stock with a stated value of $1,000 and a $0.25 conversion price into 400,000 common shares, and received additional common shares for accrued Series E dividends. During February 2026, he exchanged 500,000 warrants with a $0.50 exercise price for 500,000 warrants at $0.20, then exercised the new warrants for 500,000 common shares upon payment of $100,000, while extending the expiration of 500,000 warrants at $0.65 by one year. Following the latest reported transactions, he directly holds 21,053,099 shares of common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Imhoff John E

(Last) (First) (Middle)

5853 PEACHTREE CORNERS EAST

SUITE B

(Street)

PEACHTREE CORNERS GA 30092

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GUIDED THERAPEUTICS INC [ GTHP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/18/2025		C(1)		195,460	A	$0.07	19,658,955	D
Common Stock	01/05/2026		J(2)		25,338	A	(2)	19,684,293	D
Common Stock	02/02/2026		C(3)		312,720	A	$0.07	19,997,013	D
Common Stock	02/25/2026		X		500,000	A	(4)	20,497,013	D
Preferred Series E Stock	02/27/2026		J(5)		100	D	(5)	0	D
Common Stock	02/27/2026		J(5)		400,000	A	(5)	20,897,013	D
Common Stock	02/27/2026		C(6)		156,086	A	$0.07	21,053,099	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Convertible Promissory Note	$0.07	12/18/2025		C(1)			195,460(1)	11/28/2025	02/28/2027	Common Stock	195,460(1)	(1)	150,000(1)	D
Convertible Promissory Note	$0.07	02/02/2026		C(3)			312,720(3)	01/30/2026	02/28/2027	Common Stock	312,720(3)	(3)	130,000(3)	D
Warrants	$0.65	02/25/2026		J(4)			500,000	09/01/2022	09/01/2026	Common Stock	500,000	(4)	0	D
Warrants	$0.65	02/25/2026		J(4)		500,000		02/25/2026	09/01/2027	Common Stock	500,000	(4)	500,000	D
Warrants	$0.5	02/25/2026		J(4)			500,000	09/01/2022	09/01/2026	Common Stock	500,000	(4)	0	D
Warrants	$0.2	02/25/2026		J(4)		500,000		02/25/2026	02/25/2026	Common Stock	500,000	(4)	500,000	D
Warrants	$0.2	02/25/2026		X			500,000	02/25/2026	02/25/2026	Common Stock	500,000	(4)	0	D
Convertible Promissory Note	$0.07	02/27/2026		C(6)			156,086(6)	02/27/2026	02/28/2027	Common Stock	156,086(6)	$0.07(6)	120,000(6)	D

Explanation of Responses:

1. On December 18, 2025, Dr. Imhoff converted $13,682.19 outstanding under a September 25, 2025 Convertible Promissory Note into 195,460 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $3,682.19 of accrued interest. Following the reported conversion, $150,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

2. These shares were issued for payment of accrued dividends on the reporting individual's Series E preferred stock, at a conversion price of $0.3157.

3. On February 2, 2026, Dr. Imhoff converted $21,890.41 outstanding under a September 25, 2025 Convertible Promissory Note into 312,720 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $20,000 of principal and $1,890.41 of accrued interest. Following the reported conversion, $130,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

4. During February 2026, Mr. Imhoff signed an exchange agreement pursuant to which 500,000 warrants to purchase shares of common stock with an exercise price of $0.50 were exchanged for 500,000 warrants with an exercise price of $0.20. The newly issued warrants were subsequently exercised upon payment of $100,000. In connection with the exchange agreement, the expiration date of 500,000 warrants with exercise price of $0.65 was extended for one year, until September 1, 2027.

5. On February 27, 2026, Mr. Imhoff converted 100 shares of Series E preferred stock into 400,000 shares of common stock. The Series E preferred stock had a stated value of $1,000 and $0.25 conversion price.

6. On February 26, 2026, Dr. Imhoff converted $10,926.03 outstanding under a September 25, 2025 Convertible Promissory Note into 156,086 shares of common stock at a conversion price of $0.07 per share. The amount converted consisted of $10,000 of principal and $926.03 of accrued interest. Following the reported conversion, $120,000 of principal remains outstanding under the convertible promissory note. Upon the occurrence of an event of default, the remaining balance is convertible into common stock at a variable conversion price determined in accordance with the terms of the note.

Remarks:

	/s/ John E. Imhoff	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did John E. Imhoff report for GUIDED THERAPEUTICS (GTHP)?

John E. Imhoff reported converting multiple portions of a convertible promissory note into common stock, exchanging and exercising warrants, and converting Series E preferred stock into common shares. These actions increased his direct common stock holdings in GUIDED THERAPEUTICS INC.

How many GUIDED THERAPEUTICS (GTHP) shares does John E. Imhoff hold after these Form 4 transactions?

After the latest reported transactions, John E. Imhoff directly holds 21,053,099 shares of GUIDED THERAPEUTICS INC common stock. This figure reflects accumulated conversions, exchanges, warrant exercises, and preferred stock conversions reported across the December 2025 to February 2026 activity.

What were the key note conversion terms reported by John E. Imhoff at GUIDED THERAPEUTICS (GTHP)?

Imhoff converted note balances into common stock at a conversion price of $0.07 per share. Individual conversions covered 195,460, 312,720 and 156,086 shares, turning principal plus accrued interest on a September 25, 2025 convertible promissory note into GUIDED THERAPEUTICS common equity.

What did the warrant exchange and exercise involve for GUIDED THERAPEUTICS (GTHP)?

During February 2026, Imhoff exchanged 500,000 warrants with a $0.50 exercise price for 500,000 warrants at $0.20, then exercised the new warrants for 500,000 common shares upon payment of $100,000. The expiration of 500,000 warrants at $0.65 was extended by one year.

How did John E. Imhoff’s Series E preferred stock affect GUIDED THERAPEUTICS (GTHP) common shares?

Imhoff converted 100 shares of Series E preferred stock, with a stated value of $1,000 and a $0.25 conversion price, into 400,000 common shares. He also received additional common shares issued as payment of accrued dividends on his Series E preferred holdings.

Over what period were these GUIDED THERAPEUTICS (GTHP) insider transactions reported?

The reported transactions span from December 18, 2025 through February 27, 2026. Over this period, Imhoff executed multiple note conversions, a warrant exchange and exercise, a preferred stock conversion, and other restructuring-type entries affecting his GUIDED THERAPEUTICS common stock position.